論文・総説 - 末永 光邦

分割表示  324 件中 141 - 160 件目  /  全件表示 >>
  1. Sugita Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi, Mae Yutaro, Toya Wataru, Hagino Akane, Suzuki Kenichi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hama Toshihiro. Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer ANTICANCER RESEARCH. 2015.07; 35 (7): 4059-4062.

  2. Nakayama Izuma, Suenaga Mitsukuni, Wakatsuki Takeru, Ichimura Takashi, Ozaka Masato, Takahari Daisuke, Shinozaki Eiji, Chin Keisho, Ueno Masashi, Mizunuma Nobuyuki, Yamaguchi Toshiharu. Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2015.07; 76 (1): 133-139. ( PubMed, DOI )

  3. Nakayama Izuma, Chin Keisho, Kumekawa Yosuke, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Suenaga Mitsukuni, Ozaka Masato, Shinozaki Eiji, Mizunuma Nobuyuki. Clinical features and outcome of advanced or metastatic gastric cancer in young adult, analysis of 97 cacses JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

  4. Chin Keisho, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Ichimura Takashi, Wakatsuki Takeru, Matsushima Tomohiro, Mizunuma Nobuyuki. Outcome of marked tumor marker increase in patients with advanced gastric cancer during chemotherapy without progression JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

  5. Ichimura Takashi, Chin Keisho, Shinozaki Eiji, Suenaga Mitsukuni, Ogura Mariko, Matsushima Tomohiro, Mizunuma Nobuyuki. The long term survival benefit of salvage chemoradiotherapy for local recurrence of esophageal cancer after curative surgery JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

  6. Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Ogura Mariko, Ozaka Masato, Kumekawa Yosuke, Chin Keisho, Fujimoto Yoshiya, Ueno Masashi, Mizunuma Nobuyuki. The transition of adjuvant chemotherapy for stage III colorectal cancer: A single institute experience in Japan. JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

  7. Suenaga Mitsukuni, Nishina Tomohiro, Mizunuma Nobuyuki, Yasui Hisateru, Ura Takashi, Denda Tadamichi, Ikeda Junichi, Esaki Taito, Nishisaki Hogara, Takano Yoshinao, Sugiyama Yasuyuki, Muro Kei. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802) BMC CANCER. 2015.03; 15 176. ( PubMed, DOI )

  8. Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu. A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study). JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  9. Kumekawa Yosuke, Wakatsuki Takeru, Osumi Hiroki, Matsushima Tomohiro, Nakayama Izuma, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Mizunuma Nobuyuki. ACEIs/ARBs to improve survival in advanced gastric cancer patients receiving S-1 plus cisplatin. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  10. Yamada Ikuhiro, Ozaka Masato, Ishii Hiroshi, Sasahira Naoki, Takano Kouichi, Matsuyama Masato, Sasaki Takashi, Saito Kei, Osumi Hiroki, Suenaga Mitsukuni, Igarashi Masahiro. A retrospective study of FOLFOX in the treatment of patients with advanced duodenal adenocarcinoma: A Japanese single-center experience. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  11. Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Matsusaka Satoshi, Takahari Daisuke, Ichimura Takashi, Kumekawa Yosuke, Nakayama Izuma, Matsushima Tomohiro, Mizunuma Nobuyuki, Sano Takeshi, Yamaguchi Toshiharu, Ishikawa Yuichi. Association between intratumoral HER2 heterogeneity (IHH) and trastuzumab (T-mab) efficacy in HER2 positive-gastric cancer (GC). JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  12. Chin Keisho, Yamamoto Yorimasa, Fujisaki Junko, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Mizunuma Nobuyuki. Endoscopic response evaluation of gastric primary lesion for chemotherapy compared to CT in advanced gastric cancer JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  13. Kawakami Kazuyoshi, Yokokawa Takashi, Sugita Kazuo, Hagino Akane, Suzuki Kenichi, Oniyama Sayaka, Kohdo Satoshi, Machida Yohiaki, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Tohiharu, Hama Toshihiro. Patient's self-reported adherence to capecitabine on XELOX as adjuvant therapy for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  14. Shinozaki Eiji, Miki Yoshio, Ueno Masashi, Igarashi Masahiro, Suenaga Mitsukuni, Chin Keisho, Ozaka Masato, Ogura Mariko, Takahari Daisuke, Ichimura Takashi, Wakatsuki Takeru, Mizunuma Nobuyuki. Phenotypic differences among RAS mutational variations in colorectal cancer (CRC): Analysis of 1,001 patients in single institute. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  15. Nakayama Izuma, Shinozaki Eiji, Wakatsuki Takeru, Kumekawa Yosuke, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Ozaka Masato, Suenaga Mitsukuni, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Toshiharu. The significance of EGFR pathway mutations for the efficacy of first line treatment with bevacizumab in metastatic colonrectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  16. Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer DRUG DESIGN DEVELOPMENT AND THERAPY. 2015; 9 1653-1662. ( PubMed, DOI )

  17. Suenaga Mitsukuni, Mizunuma Nobuyuki, Shinozaki Eiji, Matsusaka Satoshi, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab ONCOTARGETS AND THERAPY. 2015; 8 243-249. ( PubMed, DOI )

  18. Ohhara Yoshihito, Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu. Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer ONCOTARGETS AND THERAPY. 2015; 8 529-537. ( PubMed, DOI )

  19. Sato Yasuyoshi, Matsusaka Satoshi, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients ONCOTARGETS AND THERAPY. 2015; 8 3329-3336. ( PubMed, DOI )

  20. Osumi Hiroki, Matsusaka Satoshi, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki. Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab ONCOTARGETS AND THERAPY. 2015; 8 2005-2013. ( PubMed, DOI )

このページの先頭へ▲